Put companies on watchlist
Aspermont Ltd
ISIN: AU000000ASP3
WKN: A0NGFS
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Aspermont Ltd · ISIN: AU000000ASP3 · EQS - Analysts (23 News)
Country: Germany · Primary market: Australia · EQS NID: 16465
24 February 2023 12:01PM

Aspermont Ltd (von GBC AG): Buy


Original-Research: Aspermont Ltd - von GBC AG

Einstufung von GBC AG zu Aspermont Ltd

Unternehmen: Aspermont Ltd
ISIN: AU000000ASP3

Anlass der Studie: Research Report (Anno) Empfehlung: Buy
Kursziel: 0.10 AUD
Kursziel auf Sicht von: 31.12.2023
Letzte Ratingänderung:
Analyst: Julien Desrosiers, Matthias Greiffenberger

XaaS powerhouse in the making. 64% Gross Profit Margin. Record FY2022 results.
 
FY net results impacted by one-time event. The company has posted their highest EBITDA results with 2.1M AUD but ended the financial year with a net loss of (0.31M AUD) due to a 700k write-off of the Blue Horseshoe investment.
 
Strong cash position. The company has over AUD 6.6M cash on hand.  
High gross margin maintained. The company has maintained a 64% gross margin for the FY 2022 compared to 65% for FY 2021.  
Stronger EBITDA margin. The company increased their EBITDA margin from 10% for the FY2021 to 12% for the FY2022.
 
Increase in recurring revenues. Aspermont grew their recurring revenues base from 70% to 75% YoY for 2022.
 
Continued growth. The company is growing at a double-digit rate across the XaaS KPIs board. Most importantly, their subscribers' ARPU has increased by 28% to a record $1538.
 
Delivering on promises:  The company has exceeded all their FY2022 guidance.
 
25 consecutive quarters of growth. The CaaS model is still growing, such as total revenues and earnings.
 
Based on our DCF model, with an updated market risk premium, we reviewed our price target to 0.10 AUD / 0.07 EUR (previously: 0.11 AUD / 0.08 EUR) per share.

Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/26465.pdf

Kontakt für Rückfragen
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (5a,7,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter: http://www.gbc-ag.de/de/Offenlegung
+++++++++++++++
Date and time of completion of this research: 24.02.2023 11:00 Date and time of first distribution: 24.02.2023 12:00 Target price valid until: max. 31.12.2023

-------------------übermittelt durch die EQS Group AG.-------------------

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

Visual performance / price development - Aspermont Ltd
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.